0.75Open0.75Pre Close0 Volume2 Open Interest50.00Strike Price0.00Turnover423.02%IV75.24%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type0.1420Delta0.0183Gamma38.61Leverage Ratio-0.3544Theta0.0003Rho5.48Eff Leverage0.0065Vega
Spyre Therapeutics Stock Discussion
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
No comment yet